G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma.

Xiao-Dong Huang,Li-Sheng Wang,Na Liu,Ying Zhang,Pei-Yu Li,Shao-Xia Wang,Can-Rong Lu,Rong-Hua Yin,Feng-Jun Xiao,Qing-Fang Li

doi:10.1007/s13277-016-5220-x

Xiao-Dong Huang, Li-Sheng Wang + Show 8 more

Open Access

https://doi.org/10.1007/s13277-016-5220-x

Copy DOI

Journal: Tumor Biology	Publication Date: Jul 26, 2016
Citations: 19	License type: CC BY 4.0

Affiliation: Chinese PLA General Hospital

Abstract

Liposarcoma(LPS) is the most common type of soft tissue sarcoma accounting for 20 % of all adult sarcomas. However, the molecular pathogenesis of this malignancy is still poorly understood. Here, we showed that GPS2 expression was downregulated in LPS and correlated with the prognosis of this disease. In vitro study showed that knockdown of GPS2 resulted in enhanced proliferation and migration of LPS cell line SW872, without significant influence of cell death. Conclusively, our results suggest that GPS2 may act as a tumor suppressor in LPS and serve as a potential prognosis marker for this disease.

Highlights

Liposarcoma (LPS) is the most common subtype of soft tissue sarcoma, accounting for 24 % of extremity and 45 % of retroperitoneal soft tissue sarcomas [1]
Our results indicated that G protein pathway suppressor 2 (GPS2) act as a tumor suppressor in LPS and it may serve as a prognosis marker in this disease
To explore the potential role of GPS2 in liposarcomas, we collected 14 LPS samples and their paired normal adipose tissues. qPCR analysis showed that the mRNA levels of GPS2 were significantly lower in tumor samples than their normal control (Fig. 1a)

Summary

Introduction

Liposarcoma (LPS) is the most common subtype of soft tissue sarcoma, accounting for 24 % of extremity and 45 % of retroperitoneal soft tissue sarcomas [1]. WDLPS are low-grade tumors with a more indolent course, while DDLPS are high-grade, aggressive tumors with a 15– 20 % risk of distant metastasis and approximately 30 % 5-year survival rate [4]. There are still 58 to 80 % of patients with DDLPS of the retroperitoneum will succumb to locally recurrence or metastasis within 5 years [7]. It is of great urgency to develop effective targeted therapies to improve outcomes of patients with liposarcoma. It has been hampered by a lack of understanding of the pathogenesis of this disease

Methods

Results

Conclusion